Report: Global diabetes and obesity therapeutics market to double by 2022

1 September 2016 (Last Updated September 1st, 2016 18:30)

The global market for diabetes mellitus and obesity is forecast to increase from $70.8bn in 2015 to $163.2bn by 2022, according to a new report by GBI Research.

The global market for diabetes mellitus and obesity is forecast to increase from $70.8bn in 2015 to $163.2bn by 2022, according to a new report by GBI Research.

Titled “Global Diabetes and Obesity Drugs Market to 2022 – Insulins and GPCRs Retain Commercial Prominence, While High Unmet Need Remains in Weight Loss Treatment”, the report attributes this growth to a number of type 2 diabetes mellitus (T2DM) therapeutics in pipeline.

The majority of the T2DM therapeutics in the pipeline are indicated for type 1 diabetes mellitus (T1DM) and T2DM. Drugs in these segments are expected to significantly contribute to market growth, with some expected to achieve blockbuster status, opines GBI Research associate analyst Callum Dew.

Some of the drugs that have been approved and are in the pipeline include Tresiba (insulin degludec), Invokana (canagliflozin) and NN-9535 (semaglutide).

"Some of the drugs that have been approved and are in the pipeline include Tresiba (insulin degludec), Invokana (canagliflozin) and NN-9535 (semaglutide)."

Johnson & Johnson’s Invokana is expected to be a leader in the disease cluster, reach $3.23bn by 2022 and is set to be approved for T1DM, T2DM and obesity.

Rise in global incidence of obesity and its subsequent impact on T2DM incidence is a major reason behind the anticipated market growth, adds Callum Dew.

Drugs indicated for the treatment of obesity currently do not have a large market presence. Some products, however, are in the pipeline, while the majority are in early stages of development.

Existing drugs such as Januvia, Novolog and Invokana will dominate the diabetes mellitus and obesity market, but four of the forecasted top ten best-selling drugs of 2022 will be new, the report adds. Some of these products include dapagliflozin propanediol plus saxagliptin, NN-9535, and LixiLan.